SCHEMBL4909117

SCHEMBL4909117

Cc1ccc(F)c(OCC(=O)Nc2ccccc2C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
KDM4E B2RXH2 3/20 0.54
POLB P06746 3/20 0.54
RAB9A P51151 3/20 0.54
CTDSP1 Q9GZU7 1/20 0.53
NOD2 Q9HC29 1/20 0.53
NPC1 O15118 2/20 0.53
ALDH1A1 P00352 3/20 0.52
TRPM4 Q8TD43 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ATM Q13315 1/20 0.52
TP53 P04637 2/20 0.52
WDR5 P61964 1/20 0.51
G6PD P11413 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4918852 0.88 MEN1 (0.67) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4649755 0.86 HCAR2 (0.59) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4912020 0.85 KMT2A (0.60) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL8689129 0.85 HCAR2 (0.60) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4915025 0.83 NPC1 (0.67) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4650573 0.83 HCAR2 (0.56) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4650515 0.81 TP53 (0.62) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4650476 0.81 HCAR2 (0.59) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL4650577 0.81 HCAR2 (0.56) HCAR2MEN1KMT2ACASP3SENP8
SCHEMBL5150684 0.80 MEN1 (0.72) HCAR2MEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 HCAR2 103/4885MEN1 3867/4885KMT2A 1394/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 HCAR2 103/4885MEN1 3867/4885KMT2A 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.